Incanthera, the drug development and targeted cancer medicines company, (“Incanthera” or “the Company”), is pleased to confirm it has been granted patents in Great Britain and the United States for its programme, ICT03-Es5.
The Company’s promising programme, ICT03-Es5, focuses on the development of a new anti-cancer agent.
The anti-cancer agent is a pro-drug activated by a specific enzyme found to be over-expressed in certain solid tumours. The molecule is designed to be inert until activated at the site of a tumour when it is then able to kill cancer cells.
Pre-clinical in vitro and in vivo data are very encouraging, leading the Company to prepare for a regulatory driven phase of development toward Phase 1 trial in humans. Initially, this programme is targeting liver and breast cancers but has the potential to be evaluated in some paediatric indications.
Simon Ward, Chief Executive Officer of Incanthera, commented:
“Confirming protection in Great Britain and the United States for our ICT03-Es5 programme is very important to the Company and its commercial ambitions.
This patent offers exclusivity in this key area of cancer treatment and secures two very important markets in the US and GB.
We believe our continuous efforts to bring novel anti-cancer agents to commercialisation will offer improved treatment options in the field of oncology.”
Isobel Finnie, Partner, at Haseltine Lake LLP, European Patent and Trade Mark Attorneys, said:
“It's been my pleasure to assist Incanthera in obtaining rapid grant of patents, embracing their lead compound, Es5, and related compounds, from both the United States Patent and Trademark Office (USPTO) and the UK Intellectual Property Office (UKIPO).
As these patent offices are respected for their patent examination standards, this confirms that Incanthera's anti-cancer therapeutics are cutting edge technology.”
For further information, please contact:
Tim McCarthy, Chairman
Simon Ward, Chief Executive Officer
Notes to Editors
Established in 2010, Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies.
Operating from Manchester, with research facilities in Bradford and Salford, Incanthera was established from the University of Bradford’s Institute of Cancer Therapeutics (www.cancer.brad.ac.uk) to develop oncology treatments from a low cost base via a productive pipeline of early stage technology opportunities.
Managed by a team of experienced individuals drawn from commercial, scientific and regulatory backgrounds, the team also has experience in the establishment, growth and exit of small to medium sized companies.
The website at www.incanthera.com has been designed to showcase the Company’s outstanding expertise in cancer therapeutic technologies.